Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202931 | 0.94 | ALOX5AP (0.38) | ALOX5APFEN1AKR1C3AKR1C2GRM2 | |
| SCHEMBL20202941 | 0.94 | GSK3B (0.34) | GSK3B | |
| SCHEMBL17083207 | 0.91 | ALOX5AP (0.34) | ALOX5APFEN1GRM2 | |
| SCHEMBL20202949 | 0.89 | GRM2 (0.33) | ALOX5APFEN1GRM2 | |
| SCHEMBL20202933 | 0.88 | ALOX5AP (0.36) | ALOX5APFEN1AKR1C3AKR1C2GRM2 | |
| SCHEMBL20202935 | 0.88 | GSK3B (0.33) | GSK3B | |
| SCHEMBL20202946 | 0.88 | ALOX5AP (0.39) | ALOX5APFEN1AKR1C3AKR1C2GRM2 | |
| SCHEMBL20202928 | 0.87 | GSK3B (0.33) | GSK3B | |
| SCHEMBL20202932 | 0.87 | RARB (0.37) | ALOX5APFEN1AKR1C3AKR1C2GRM2 | |
| SCHEMBL20202945 | 0.87 | RARB (0.37) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315727-B2 | Compound having fluorinated naphthalene structure and liquid crystal composition of the same | DIC Corporation (Tokyo) (JP) | 2016-04-19 | — | — | US | disclosed |
| US-9315727-B2 | Compound having fluorinated naphthalene structure and liquid crystal composition of the same | DIC Corporation (Tokyo) (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | DIC CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | DIC CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | TNK1, CTNND1, FLI1 | ALOX5AP 3554/4885FEN1 564/4885GSK3B 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.